

Biological E gears up for new phase of India's vaccination drive

16 March 2022 | News

Biological E's production capacity is up to 1 billion vaccines annually

On the occasion of National Immunisation Day on 16 March and in an effort to support the Government's ongoing efforts to protect our country against COVID-19, Hyderabad-based Biological E is geared to facilitate the first phase of the vaccination drive for the 12 to 15 years' Indian population through its vaccine CORBEVAX. Biological E collaborated with the Texas Children's Hospital and the Baylor College to develop CORBEVAX vaccine.

Dynavax, Inc from US supported CORBEVAX development by providing the adjuvant and THSTI Delhi conducted key immunogenicity testing as part of a comprehensive clinical trial development plan.

BIRAC, a division of Department of Biotechnology, Bill & Melinda Gates Foundation and Coalition for Epidemic Prevention and Innovation (CEPI) provided partial funding during clinical development.

CORBEVAX is a recombinant protein subunit vaccine against the novel coronavirus and has been given emergency use authorisation (EUA) for children aged 12-18 years and adults from 18-80 yrs. The vaccine is administered through intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees Celsius.

Biological E had begun the manufacturing CORBEVAX for stockpiling after approval, based on the favourable clinical

evidence and review by experts. Multiple Biological E. Limited facilities in Hyderabad are currently producing and will continue to produce the vaccine. The group will leverage its robust pan India presence and partner with the State Governments, hospitals and Medical institutions to leave no stone unturned in facilitating the uninterrupted supply of the COVID-19 vaccine. To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India.